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ABSTRACT 24 
Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole. Population 25 
analyses have demonstrated relatively predictable pharmacokinetic (PK) behavior in 26 
diverse patient populations. We evaluated the impact of mucositis on the oral 27 
isavuconazole exposure using population PK modeling.  28 
METHODS: We evaluated patients treated in two phase 3 trials of isavuconazole, 29 
SECURE for treatment of invasive aspergillosis (IA) and other filamentous fungi and 30 
VITAL for patients with mucormycosis, invasive fungal disease (IFD) caused by other 31 
rare fungi, or IA and renal impairment. Mucositis was reported by site investigators and 32 
its impact on oral bioavailability was assessed. Use of the oral formulation was at the 33 
discretion of the investigator. Patients with plasma samples collected during the use of 34 
isavuconazonium sulfate were included in the construction of population PK model. 35 
RESULTS: Of 250 patients included, 56 patients had mucositis at therapy onset or as an 36 
adverse event during oral isavuconazole therapy. Oral bioavailability was comparable of 37 
98.3% and 99.8%, respectively. The average drug exposures (AUCave) calculated from 38 
either the mean or median parameter estimates were not different between patients with 39 
and without mucositis. Mortality and overall clinical response was similar between 40 
patients receiving oral therapy with and without mucositis.  41 
CONCLUSION: Isavuconazole exposures and clinical outcomes in this subset of patients 42 
with mucositis who were able to take oral isavuconazonium sulfate were comparable to 43 
those without mucositis, despite the difference in oral bioavailability. Therefore, 44 
mucositis may not preclude use of the oral formulation of isavuconazonium sulfate.  45 
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INTRODUCTION 47 
Invasive mould diseases (IMDs) are life-threatening conditions that require timely 48 
and intensive treatment. Patients with hematological disorders or who have undergone 49 
hematopoietic stem cell transplantation (HSCT) are a leading risk group for IMDs. Anti-50 
neoplastic chemotherapy for acute myeloid leukemia (AML) or acute lymphocytic 51 
leukemia (ALL) and conditioning regimens for HSCT often cause mucosal disruption of 52 
the gastrointestinal (GI) tract (i.e. mucositis) that may compromise oral bioavailability 53 
(1). An evaluation of the impact of mucositis on the oral absorption of antifungal agents 54 
is required to ensure optimal antifungal therapy (2). 55 
 Isavuconazonium sulfate, the water-soluble prodrug of the triazole antifungal 56 
agent isavuconazole, is approved by the US FDA for the treatment of invasive 57 
aspergillosis (IA) and invasive mucormycosis (IM) and by the EMA for the treatment of 58 
IA, and for IM in patients for whom amphotericin B is inappropriate (3, 4). The clinical 59 
formulations include both intravenous and oral capsules. The pharmacokinetics have 60 
been well characterized from sub-studies embedded in clinical trials (5-8). The pivotal 61 
clinical trials included more than 400 patients with >60% with hematological 62 
malignancies or other conditions that required intensive chemotherapy and the potential 63 
for mucositis (9, 10).   64 
 Here, we examine the impact of mucositis on the bioavailability and drug 65 
exposure following the administration of oral isavuconazonium sulfate.  We fitted a 66 
population pharmacokinetic model to the plasma concentrations from patients receiving 67 
oral isavuconazole in patients with and without mucositis and used this model to 68 
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bioavailability and the ultimate drug exposure.  We consider the potential impact for 69 
dosing and therapeutic drug monitoring of isavuconazole in the setting of mucositis. 70 
  71 
 o
n
 M
arch 23, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 5
METHODS 72 
Study design. Patients treated with isavuconazonium sulfate from two Phase 3 73 
clinical trials, SECURE and VITAL, were eligible for inclusion if plasma concentrations 74 
were available. The SECURE trial (ClinicalTrials.gov identifier: NCT00412893) 75 
evaluated the efficacy and safety of isavuconazole compared with voriconazole for the 76 
primary treatment of invasive mould disease caused by Aspergillus spp. and other 77 
filamentous fungi (9). The VITAL trial (ClinicalTrials.gov identifier: NCT00634049) 78 
evaluated the efficacy and safety of isavuconazole for the treatment of IA in patients with 79 
renal impairment and in patients with IFD caused by Mucorales and other emerging 80 
moulds, yeasts, and dimorphic fungi (10). Eligibility criteria for both studies are detailed 81 
elsewhere (9, 10). Patients received a loading regimen of isavuconazonium sulfate at a 82 
dose of 372 mg (equivalent to isavuconazole 200 mg) every 8 h for the first 48 h. In the 83 
SECURE trial, the loading dose was required to be administered intravenously (i.v.), 84 
while in the VITAL trial treatment could commence using either the i.v. or oral 85 
formulation. The maintenance regimen for both studies was i.v. or oral isavuconazonium 86 
sulfate 372 mg once daily for up to 84 or 180 days, respectively. Patients received i.v. or 87 
oral drug at the discretion of site investigators. 88 
Identification of Patients with Mucositis. The medical history (MH) and adverse 89 
event (AE) records from the case report forms were reviewed for MedDRA preferred 90 
terms suggestive of “mucositis” or “stomatitis” (e.g. mucosal inflammation, radiation 91 
mucositis, stomatitis, gastrointestinal inflammation). From there, the patients were further 92 
reviewed to determine the degree of likelihood that the MH and AE reported represented 93 
significant disease, such as recent radiation therapy or intensive chemotherapy. Patients 94 
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with mucositis were only included if administration of the oral formulation occurred 95 
during the episode of mucositis AND plasma PK concentrations coincided with the oral 96 
administration and episode of mucositis. Patients without mucositis with plasma PK 97 
measurements during oral administration were classified as non-mucositis patients. 98 
Plasma PK sampling. Blood samples were collected on treatment days 7, 14, 42, 99 
and end of therapy (EOT) in both trials. Collection was targeted for 24 hours after the 100 
start of the infusion or the oral dose on the previous day (i.e., trough concentration). Full 101 
24-hour profiles were obtained from a subset of 43 patients (including 6 patients with 102 
mucositis). After collection, samples were processed immediately and stored at –80°C 103 
until shipment to the central research laboratory. Isavuconazole concentrations were 104 
measured at the completion of the study using a validated LC-MS/MS method as 105 
previously described (5). 106 
Population Pharmacokinetic (PPK) Modeling. Raw plasma concentration data 107 
from the 2 groups during oral administration that was collected after Day 7 were 108 
compared to determine if any trends in the data were observed. A PPK model was 109 
developed using non-parametric estimation using Pmetrics (v1.4.1, University of 110 
Southern California, Los Angeles, CA, USA) (11). The model-fitting process included 111 
evaluation of both 2- and 3-compartment models including absorptive compartments and 112 
a lag-time. The presence of mucositis (yes=1, no=0) was used as a covariate on oral 113 
bioavailability (F) as a secondary equation, which took the following form: 114 
ܨ = ܨ1 ∙ ሺ1 − ܯܷܥሻ +  ܨ12 ∙ ܯܷܥ 
where, F1 refers to the oral bioavailability in patients without mucositis (MUC=0) and 115 
F12 refers to the oral bioavailability in patients with mucositis (MUC=1).  116 
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Data were weighted by the inverse of the estimated assay variance. The final 117 
model was assessed by a visual inspection of the observed-versus-predicted concentration 118 
values before and after the Bayesian step, the coefficient of determination (r2) from the 119 
linear regression of the observed-versus-predicted values, as well as estimates for bias 120 
(mean weighted error) and precision (adjusted mean weighted squared error).  121 
The average AUC (AUCave) for each patient was calculated using the Bayesian 122 
posterior parameter estimates from the final model using the trapezoidal rule in Pmetrics. 123 
AUCave was calculated by determining the total AUC over the entire dosing period and 124 
dividing by the number of days of therapy for each patient. Statistical comparisons were 125 
performed in MYSTAT 12 version 12.02 (https://systatsoftware.com) and GraphPad 126 
Prism version 6.0h (http://www.graphpad.com). 127 
Exposure-Response Analysis. The AUCave for patients with and without mucositis 128 
were compared by patient outcomes defined as All-Cause Mortality through Day 42 or 129 
Overall Response to explore if any impact on exposure was associated with differences in 130 
response. Statistical comparisons were performed in MYSTAT 12 (version 12.02, 131 
http://www.systat.com). 132 
  133 
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RESULTS 134 
Study Population. A total of 250 patients were included in the analysis of which 135 
56 had mucositis. Figure 1 shows the flow of patient inclusion in the study. The majority 136 
of the mucositis patients had a hematologic malignancy (89.3%) that was active at the 137 
time of enrollment and were neutropenic at the start of antifungal treatment (78.2%) 138 
(Table 1). Only 6 patients did not have a hematological malignancy [aplastic anemia 139 
(n=3), uterine leiomyosarcoma (n=1), X-linked adrenomyeloneuropathy (n=1), squamous 140 
cell carcinoma of the tongue (n=1)]. A quarter (26.8%) of the patients with mucositis had 141 
received a HSCT. Sixteen percent of mucositis patients had baseline renal impairment 142 
(eGFR-MDRD < 60 mL/min/1.73m2) compared with 27.6% of those without mucositis. 143 
The majority of the overall population were males (62%), Caucasian (78.8%), and the 144 
average age (± SD) and weight (± SD) were 50.3 ± 16.1 years and 70.0 ± 18.3 kg, 145 
respectively. 146 
Type of Fungal Infection in Patients with Mucositis. Thirty-two patients had 147 
proven or probable IA and 7 patients had possible IA (with appropriate host factors, 148 
clinical features but no mycological evidence of disease). Eight patients had proven or 149 
probable infection caused by various mould and rare yeasts including Mucorales (n=1), 150 
Fusarium spp. (n=3), Culvularia lunata (n=1), Alternaria spp. (n=1), Acremonium spp. 151 
(n=1), and Trichosporon spp. (n=1). Five patients did not have enough evidence for 152 
probable or proven IFD after review of the Data Review Committees. 153 
PPK Model. Comparisons of the raw plasma concentrations for the patients with 154 
mucositis and patients without mucositis during oral administration beyond Day 7 155 
revealed a statistical difference between the 2 groups (Fig. 2), although the 156 
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concentrations largely overlapped. A 2-compartment model including an absorptive 157 
compartment fit the data well. An illustration of the structural model is provided in Fig. 3 158 
where the first compartment represents the gut (oral compartment) and the second 159 
representing the central compartment. The fit of the model to the data was acceptable 160 
based on visual inspection of the observed-versus-median predicted plots and the 161 
coefficient of determination (r2) of 0.813 after the Bayesian step (Fig. 4). The estimates 162 
of bias and imprecision were also acceptable (0.11 and 0.938, respectively). The 163 
observed-versus-mean predicted plots showed similar statistics with a coefficient of 164 
determination (r2) of 0.792 (slope = 0.976) after the Bayesian step. The median parameter 165 
estimates are included in Table 2.  166 
 Comparison of Oral Bioavailability. The mean (range) oral bioavailability (F) 167 
estimates for mucositis and non-mucositis patients were 86.0% (50.3-99.7%) and 97.4% 168 
(70.2-99.9%), respectively. Comparison of the mean and median bioavailability estimates 169 
for the two populations demonstrated a significant difference between the 2 groups (p < 170 
0.001) (Fig. 5). However, this 11.4% difference in bioavailability did not have a 171 
significant impact on the distribution of exposures (AUCave) between the two groups 172 
(p=0.706) (Fig. 6).  173 
 All-Cause Mortality through Day 42. All-cause mortality through treatment day 174 
42 for the patients with and without mucositis was 7.1% (4/56) and 14.4% (28/194), 175 
respectively. The oral bioavailability and AUCave were 83.6% and 91.3 mgh/L, 92.7% 176 
and 164.9 mgh/L, 99.7% and 56.5 mgh/L, and 99.7% and 216.9 mgh/L for the four 177 
patients with mucositis who died. The median bioavailability estimates for the non-178 
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mucositis patients that died were all above 90% except for one patient with an estimate of 179 
70.2%. The mean AUCave was 100.5 mgh/L and ranged from 34.9-369.1 mgh/L. 180 
Overall Response at the End of Therapy (EOT). Overall Response at the EOT was 181 
available for 232 mITT patients in the analysis. Fifty-eight percent [n=43; 95% CI 42.13, 182 
72.99] and 42.9% [n=189, 95% CI 35.68, 50.42] of the patients with and without 183 
mucositis had a successful response, respectively. In the mucositis patients who failed at 184 
the EOT (n=25), the mean oral bioavailability was 84.9 ± 17.9%, (range 50.4-99.7%; 185 
median 90.3%) and the mean AUCave was 117.9 ± 69.4 mgh/L, (range 45.9-315.5 186 
mgh/L; median 94.2 mgh/L). Six of the patients (n=18; 33%) who failed at the EOT had 187 
oral bioavailability estimates < 80% (range 50.4-69.5%) with AUCave values ranging 188 
from 45.9-176.3 mgh/L and 8 of the patients (n=25; 32%) with successful responses at 189 
the end of therapy had bioavailability estimates of <80% (range 50.3-75.5%) with 190 
AUCave ranging from 48.2-155.2 mgh/L. 191 
  192 
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DISCUSSION  193 
Biological factors that have an impact on drug absorption include the pH along 194 
the GI tract, tissue perfusion, the presence of bile and mucus, the surface area per volume 195 
of the lumen, and the epithelial integrity. Mucositis manifests as erythema, inflammation, 196 
ulcerations, and hemorrhage of the mucosal surfaces of the GI tract and causes gastric 197 
motility dysfunction. This mucosal disruption can significantly affect drug absorption 198 
after the oral administration of medications. Using oral medications in the setting of 199 
mucositis requires an understanding of the determinants of drug absorption. 200 
Table 3 summarizes the determinants of oral bioavailability for triazole antifungal 201 
agents. Isavuconazole and fluconazole have similar characteristics that include the 202 
absence of clinically relevant effect on absorption from food, changes in pH, or increases 203 
in GI motility (3, 12, 13). Posaconazole and itraconazole oral solutions should be 204 
administered with high-fat meals, carbonated soda, or nutritional supplements (2, 14-19).  205 
Plasma concentrations are decreased when gastric acidity is reduced (2, 14-19). 206 
Absorption of posaconazole oral solution may be improved when daily doses are 207 
fractionated compared with less frequent dosing (20). The newer posaconazole tablets are 208 
not affected by changes in gastric pH and absorption is not improved by the consumption 209 
of high-fat meals (17, 21). Voriconazole plasma concentrations are reduced when taken 210 
with food; however, absorption is not clinically significantly affected by changes in pH or 211 
by drugs such as omeprazole (22). H2-blockers were not found to cause clinically 212 
significant changes in voriconazole absorption kinetics (23).  Voriconazole exhibits 213 
decreased oral bioavailability in patients with cystic fibrosis (CF) compared to patients 214 
without CF after lung transplant (24). Thus, factors that affect the absorption of triazoles 215 
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such as mucositis differ markedly.  216 
Drugs that require food to increase bioavailability or experience decreased 217 
bioavailability with increased gastric emptying (increased gastric motility) suggest that 218 
passive diffusion is slow and likely occurs primarily from the stomach. In these 219 
circumstances, absorption is improved by longer transit times in the stomach and upper 220 
small intestine. Aside from the prodrug formulation of isavuconazole, the other azoles are 221 
limited by the insufficient dissolution in stomach prior to delivery in the duodenum, 222 
where absorption is maximal. A meal that is high in fat increases luminal volume and bile 223 
and pancreatic secretions, and delays gastric emptying. The absorption for drugs such as 224 
posaconazole may be optimized by the use a more fractionated regimen (14, 25, 26). 225 
However, studies have suggested that this may be due to the high-fat meal increasing the 226 
solubility versus delayed gastric emptying (14). Another study failed to associate factors 227 
such as P-glycoprotein on the absorption of posaconazole (27). In contrast, the absorption 228 
for isavuconazole and fluconazole (and to a lesser extent voriconazole) is not 229 
significantly influenced by these factors, suggesting passive diffusion occurs more 230 
quickly and the majority of the absorption occurs in the upper small intestine. 231 
In this analysis, the presence of mucositis did not have a significant overall impact 232 
on the clinical outcomes in the patients treated with isavuconazonium sulfate from the 233 
SECURE and VITAL trials despite the statistical differences in oral bioavailability 234 
between the groups with and without mucositis. In addition, the drug exposure between 235 
the groups was not significantly different. The results held whether mean or median 236 
parameter estimates were used for the comparisons. 237 
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The current study has several limitations. First, details on the presence or severity 238 
of mucositis were not available for the majority of patients with the condition. 239 
Quantification of severity may have allowed for a deeper understanding of the impact for 240 
the degree of mucosal disruption and the impact on oral bioavailability. Second, patients 241 
were allowed to switch back and forth from oral to intravenous medication during the 242 
treatment period. However, only patients with mucositis coinciding with oral 243 
administration were selected for analysis. Third, the administration of i.v. or oral 244 
formulations was at the discretion of the site investigators making it difficult to assess the 245 
impact of the severity of mucositis on oral bioavailability.  Patients with more severe 246 
grades of mucositis patients may have remained on i.v. therapy longer, while patients 247 
with less severe mucositis may have been switched to oral therapy. In addition, 248 
identification of mucositis patients for this study relied on the reporting of the events by 249 
the treating investigator, which could be underrepresenting the incidence in the study. We 250 
did not utilize a validated mucositis score or a biomarker, such as citrulline to capture 251 
severity as has done in other studies (28). Finally, we assumed compliance was 100%, 252 
which may be overly optimistic.  253 
These analyses are important as many patients who will be treated with 254 
isavuconazonium sulfate are at risk or could have mucositis at the onset of therapy caused 255 
by the harsh treatments used to treat their underlying co-morbidities. Patients with 256 
slightly lower bioavailability had outcomes similar to those with higher bioavailability. 257 
Therefore, use of the oral formulation of isavuconazonium sulfate during episodes of 258 
mucositis may be acceptable; however, treating physicians may consider extending 259 
isavuconazole intravenous therapy during episodes of mucositis or monitoring levels to 260 
 o
n
 M
arch 23, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 14
ensure they are within the range reported from the clinical trial. However, additional 261 
studies in this population may be warranted.  262 
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Figure Legends 397 
FIG 1. Flowchart illustrating flow of isavuconazole-treated patients into the 398 
mucositis and non-mucositis populations 399 
 400 
FIG 2. Comparison of plasma concentrations drawn during oral 401 
administration after day 7 of therapy between the mucositis and non-402 
mucositis patients. (Mann-Whitney U Test p-value = 0.0011). 403 
 404 
FIG 3. Illustration of the Structural Model: Compartment 1 represents the gut 405 
for oral administration; Compartment 2 represents the central compartment; 406 
CL, clearance; F, bioavailability; Ka, first-order absorption rate constant; Tlag, 407 
lag-time; V, volume in the central compartment; RATEIV(1) specifies infusions 408 
going directly into the central compartment. 409 
 410 
FIG 4. Observed versus median posterior predicted concentrations (mg/L) 411 
from the final model after the Bayesian step (r2= 0.813, slope = 0.98 [95%CI 412 
0.956 to 1], intercept = -0.0181 [95%CI −0.115 to 0.0792]). Dotted line is line 413 
of unity where observed concentrations equal predicted concentrations. 414 
 415 
FIG 5. There is a significant difference in the median estimates for 416 
bioavailability between the 2 groups. (Mann-Whitney U Test p-value < 417 
0.0001). 418 
 419 
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FIG 6. No significant difference in average AUCs between Mucositis and Non-420 
Mucositis Patients (p=0.706; Mann Whitney U test) (AUCs calculated from the 421 
median parameter estimates after the Bayesian step). 422 
 423 
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Table 1. Demographics, Background Disease and Duration of Therapy 424 
 Mucositis 
N=56 
Non-Mucositis 
N=194 
Total 
N=250 
Age (years)    
Median (min-max)  50 (18-79) 52 (19-92) 52 (18-92) 
Sex    
Male 32 (57%) 123 (63%) 155 (62%) 
Race    
White 48 (86%) 149 (77%) 197 (79%) 
Asian 7 (13%) 31 (16%) 38 (15%) 
Black 1 (2%) 9 (5%) 10 (4%) 
Other 0 5 (3%) 5 (2%) 
Weight (kg)    
Mean ± SD 71.7 ± 18.1 69.5 ± 18.4 70.0 ± 18.3 
Underlying Disease    
Hematological Malignancy 50 (89.3%) 101 (52.1%) 151 (60.4%) 
Active Malignancy 40 (71.4%) 76 (39.2%) 116 (46.4%) 
Allogeneic HSCT 15 (26.8%) 33 (17.0%) 48 (19.2%) 
Baseline Neutropenia 43 (78.2%) 64 (41.8%) 107 (51.4%) 
T-cell Immunosuppressants 23 (41.8%) 82 (51.9%) 105 (49.3%) 
Use of Corticosteroids 8 (14.3%) 47 (24.2%) 55 (22.0%) 
Duration of Therapy (days)    
Median (range)    
Total duration 75.5 (8-735) 83 (1-882) 82 (1-882) 
IV formulation 9 (2-45) 7 (0.5-77) 7.5 (0.5-77) 
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Oral formulation 58 (1-690) 79.8 (0.5-882) 73 (0.5-882) 
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Table 2. Median Parameter estimates from the PPK model 426 
 Mucositis Non-Mucositis 
 Mean ± SD Median Range %CV Mean ± SD Median Range %CV 
Ka (h-1) 7.0 ± 2.6 7.9 0.0-8.0 38% 6.5 ± 3.0 7.9 0.0-8.0 46% 
Cl/F (L/h) 2.2 ± 1.0 1.9 0.5-4.1 44% 2.3 ± 1.1 1.9 0.1-5.9 47% 
V/F (L) 331.4 ± 154.9 347.7 6.8-895.5 47% 354.1 ± 182.5 349.8 5.8-895.5 52% 
Lag time (h) 1.2 ± 1.2 1.0 0.0-5.0 94% 1.3 ± 1.3 1.0 0.0-5.0 103% 
F (%) 86.0 ± 18.5 98.3 50.3-99.7 21% 97.4 ± 6.9 99.8 70.2-99.9 7% 
AUCave  
(mg·h/L) 
105.3 ± 55.9 91.9 45.9-315.5 53% 114.1 ± 141.2 100.2 30.8-1944.3 124% 
Abbreviations: SD, standard deviation; Ka, first-order absorption rate constant; CL, clearance; F, bioavailability; V, volume in the central compartment, AUCave, average area-427 
under-the concentration curve. 428 
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Table 3. Comparison of factors impacting oral absorption of triazole antifungal drugs 430 
 
Isavuconazonium 
sulfate 
Voriconazole Posaconazole (15) Itraconazole (16) 
Fluconazole 
(13) 
Formulation capsule tablets solution tablets solution capsule tablet 
Water 
Solubility 
Y (prodrug) N N N Y 
Bioavailability 
(%) 
     
Healthy 
Subjects 
98 (12) 96 (29) 8-48 (fasted) 54 (fasted) 55 90 
Patients 97 (5) 64 (30)    
GI motility 
agents 
none No data found Decreases none No data found No data found 
pH Effect none none 
Decreases in 
reduced acidity 
none 
Decreased in reduced 
acidity 
none 
Food Effect none Decreases Increases Cmax and Increases none 
 o
n
 M
arch 23, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 27
concentrations concentrations 
(especially high 
fat, nutritional 
supplement or 
acidic 
carbonated 
beverage) 
AUC 
increases 16% 
and 51% with 
high fat foods 
concentrations 
Other  
F significantly lower 
in CF lung tx (23%) 
pts versus non-CF 
lung tx (63%) (24); 2 
factors significant 
association with F in 
lung tx pts: CF, post-
operative time 
(increased with 
increasing time) (24) 
Divided doses 
increases 
absorption 
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Substrate of 
Pgp 
no no yes yes yes yes no 
Abbreviations: Y: yes; N: no; GI: gastrointestinal; F: bioavailability; CF: cystic fibrosis; Pgp: P-glycoprotein 431 
 432 
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 433 
 434 
FIG 1. Flowchart illustrating flow of isavuconazole-treated patients into the 435 
mucositis and non-mucositis populations 436 
  437 
404 enrolled 
(258 SECURE + 146 VITAL)
286 with plasma concentrations
92 with mucositis
Mucositis Population:
n=56 (received PO during mucositis 
episode)
4 IV only
32 mucosotis 
onset after 
treatment or no 
PK during PO
Non-Mucositis Population:
n=194
118 without plasma concentrations
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 438 
 439 
FIG 2. Comparison of plasma concentrations drawn during oral 440 
administration after day 7 of therapy between the mucositis and non-441 
mucositis patients. (Mann-Whitney U Test p-value = 0.0011). 442 
  443 
 o
n
 M
arch 23, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 31
 444 
 445 
 446 
 447 
 448 
 449 
FIG 3. Illustration of the Structural Model: Compartment 1 represents the gut 450 
for oral administration; Compartment 2 represents the central compartment; 451 
CL, clearance; F, bioavailability; Ka, first-order absorption rate constant; Tlag, 452 
lag-time; V, volume in the central compartment; RATEIV(1) specifies infusions 453 
going directly into the central compartment. 454 
  455 
Nbolus (1) RATEIV(1) V 
CL/V 
Ka 
F 
Tlag 
 o
n
 M
arch 23, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 32
 456 
 457 
 458 
FIG 4. Observed versus median posterior predicted concentrations (mg/L) 459 
from the final model after the Bayesian step (r2= 0.813, slope = 0.98 [95%CI 460 
0.956 to 1], intercept = -0.0181 [95%CI −0.115 to 0.0792]). Dotted line is line 461 
of unity where observed concentrations equal predicted concentrations. 462 
  463 
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 464 
 465 
FIG 5. There is a significant difference in the median estimates for 466 
bioavailability between the 2 groups. (Mann-Whitney U Test p-value < 467 
0.0001). 468 
  469 
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 470 
 471 
FIG 6. No significant difference in average AUCs between Mucositis and Non-472 
Mucositis Patients (p=0.706; Mann Whitney U test) (AUCs calculated from the 473 
median parameter estimates after the Bayesian step). 474 
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